Fed. Circ. Lifts Injunction On Hanmi's Generic Nexium

Law360, Washington (October 2, 2013, 4:35 PM EDT) -- The Federal Circuit has lifted a temporary injunction barring Hanmi USA Inc. from launching its generic version of AstraZeneca’s acid reflux drug Nexium, in an appeal of a New Jersey court ruling that hindered AstraZeneca’s patent infringement claims.

The Federal Circuit vacated its prior temporary injunction in an order dated Sept. 30, allowing Hanmi’s drug, a 505(b)2 NDA esomeprazole strontium product, to be launched during the appeal of a New Jersey federal court’s claims constructions of the patents-at-issue.

“The temporary injunction is vacated,” the Federal Circuit...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.